Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution
 Back to Details

Connection

Michael Bristow to Adrenergic beta-Antagonists

This is a "connection" page, showing publications Michael Bristow has written about Adrenergic beta-Antagonists.

 
Connection Strength
  
 
 
11.559
  
  1. Parikh KS, Fiuzat M, Davis G, Neely M, Blain-Nelson P, Whellan DJ, Abraham WT, Adams KF, Felker GM, Liggett SB, O'Connor CM, Bristow MR. Dose Response of ß-Blockers in Adrenergic Receptor Polymorphism Genotypes. Circ Genom Precis Med. 2018 08; 11(8):e002210.
    View in: PubMed
    Score: 0.500
  2. Sucharov CC, Kao DP, Port JD, Karimpour-Fard A, Quaife RA, Minobe W, Nunley K, Lowes BD, Gilbert EM, Bristow MR. Myocardial microRNAs associated with reverse remodeling in human heart failure. JCI Insight. 2017 01 26; 2(2):e89169.
    View in: PubMed
    Score: 0.450
  3. Bristow MR, Saxon LA, Feldman AM, Mei C, Anderson SA, DeMets DL. Lessons Learned and Insights Gained in the Design, Analysis, and Outcomes of the COMPANION Trial. JACC Heart Fail. 2016 07; 4(7):521-535.
    View in: PubMed
    Score: 0.431
  4. Kao DP, Lowes BD, Gilbert EM, Minobe W, Epperson LE, Meyer LK, Ferguson DA, Volkman AK, Zolty R, Borg CD, Quaife RA, Bristow MR. Therapeutic Molecular Phenotype of ß-Blocker-Associated Reverse-Remodeling in Nonischemic Dilated Cardiomyopathy. Circ Cardiovasc Genet. 2015 Apr; 8(2):270-83.
    View in: PubMed
    Score: 0.392
  5. Aleong RG, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR. Prevention of atrial fibrillation by bucindolol is dependent on the beta1389 Arg/Gly adrenergic receptor polymorphism. JACC Heart Fail. 2013 Aug; 1(4):338-344.
    View in: PubMed
    Score: 0.353
  6. Bristow MR, Aleong RG. Treatment of the heart failure patient with atrial fibrillation: a major unmet need. JACC Heart Fail. 2013 Feb; 1(1):29-30.
    View in: PubMed
    Score: 0.342
  7. Aleong RG, Sauer WH, Robertson AD, Liggett SB, Bristow MR. Adrenergic receptor polymorphisms and prevention of ventricular arrhythmias with bucindolol in patients with chronic heart failure. Circ Arrhythm Electrophysiol. 2013 Feb; 6(1):137-43.
    View in: PubMed
    Score: 0.339
  8. Kao DP, Davis G, Aleong R, O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Murphy GA, Sauer W, Bristow MR. Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation. Eur J Heart Fail. 2013 Mar; 15(3):324-33.
    View in: PubMed
    Score: 0.338
  9. O'Connor CM, Fiuzat M, Carson PE, Anand IS, Plehn JF, Gottlieb SS, Silver MA, Lindenfeld J, Miller AB, White M, Walsh R, Nelson P, Medway A, Davis G, Robertson AD, Port JD, Carr J, Murphy GA, Lazzeroni LC, Abraham WT, Liggett SB, Bristow MR. Combinatorial pharmacogenetic interactions of bucindolol and ß1, a2C adrenergic receptor polymorphisms. PLoS One. 2012; 7(10):e44324.
    View in: PubMed
    Score: 0.334
  10. Bristow MR. Treatment of chronic heart failure with ß-adrenergic receptor antagonists: a convergence of receptor pharmacology and clinical cardiology. Circ Res. 2011 Oct 28; 109(10):1176-94.
    View in: PubMed
    Score: 0.313
  11. O'Connor CM, Fiuzat M, Swedberg K, Caron M, Koch B, Carson PE, Gattis-Stough W, Davis GW, Bristow MR. Influence of global region on outcomes in heart failure ß-blocker trials. J Am Coll Cardiol. 2011 Aug 23; 58(9):915-22.
    View in: PubMed
    Score: 0.309
  12. Bristow MR, Murphy GA, Krause-Steinrauf H, Anderson JL, Carlquist JF, Thaneemit-Chen S, Krishnan V, Abraham WT, Lowes BD, Port JD, Davis GW, Lazzeroni LC, Robertson AD, Lavori PW, Liggett SB. An alpha2C-adrenergic receptor polymorphism alters the norepinephrine-lowering effects and therapeutic response of the beta-blocker bucindolol in chronic heart failure. Circ Heart Fail. 2010 Jan; 3(1):21-8.
    View in: PubMed
    Score: 0.272
  13. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved beta(1)-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proc Natl Acad Sci U S A. 2006 Jul 25; 103(30):11288-93.
    View in: PubMed
    Score: 0.217
  14. Altman NL, Gill EA, Kahwash R, Meyer LK, Wagner JA, Karimpour-Fard A, Berning AA, Minobe WA, Carroll IA, Jonas ER, Slavov D, Emani S, Abraham WT, Gollah AR, Ellis SL, Taylor MRG, Graw SL, Mestroni L, McKinsey TA, Buttrick PM, Kao DP, Bristow MR. Heart Rate Reduction Is Associated With Reverse Left Ventricular Remodeling and Mechanism-Specific Molecular Phenotypes in Dilated Cardiomyopathy. Circ Heart Fail. 2025 Apr; 18(4):e012484.
    View in: PubMed
    Score: 0.197
  15. Bristow MR, Adams KF, Bauman JL, Feldman AM, Giles TD, Goldstein S, Mann DL, Talbert RL. The COMET trial. Congest Heart Fail. 2005 Jan-Feb; 11(1):39-47.
    View in: PubMed
    Score: 0.195
  16. Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation. 2004 Sep 14; 110(11):1437-42.
    View in: PubMed
    Score: 0.190
  17. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, Feldman AM. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med. 2004 May 20; 350(21):2140-50.
    View in: PubMed
    Score: 0.187
  18. Bristow MR, Feldman AM, Adams KF, Goldstein S. Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial? J Card Fail. 2003 Dec; 9(6):444-53.
    View in: PubMed
    Score: 0.181
  19. Lefkowitz RJ, Rockman HA, Shim PJ, Liu S, Ahn S, Pani B, Rajagopal S, Shenoy SK, Bouvier M, Benovic JL, Liggett SB, Ruffolo RR, Bristow MR, Packer M. How carvedilol does not activate ß2-adrenoceptors. Nat Commun. 2023 11 30; 14(1):7866.
    View in: PubMed
    Score: 0.181
  20. Bristow M. Antiadrenergic therapy of chronic heart failure: surprises and new opportunities. Circulation. 2003 Mar 04; 107(8):1100-2.
    View in: PubMed
    Score: 0.172
  21. Lowes BD, Gilbert EM, Abraham WT, Minobe WA, Larrabee P, Ferguson D, Wolfel EE, Lindenfeld J, Tsvetkova T, Robertson AD, Quaife RA, Bristow MR. Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med. 2002 May 02; 346(18):1357-65.
    View in: PubMed
    Score: 0.162
  22. Lowes BD, Tsvetkova T, Eichhorn EJ, Gilbert EM, Bristow MR. Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int J Cardiol. 2001 Dec; 81(2-3):141-9.
    View in: PubMed
    Score: 0.157
  23. Bristow MR, Shakar SF, Linseman JV, Lowes BD. Inotropes and beta-blockers: is there a need for new guidelines? J Card Fail. 2001 Jun; 7(2 Suppl 1):8-12.
    View in: PubMed
    Score: 0.152
  24. Shakar SF, Bristow MR. Low-level inotropic stimulation with type III phosphodiesterase inhibitors in patients with advanced symptomatic chronic heart failure receiving beta-blocking agents. Curr Cardiol Rep. 2001 May; 3(3):224-31.
    View in: PubMed
    Score: 0.151
  25. Bristow MR. What type of beta-blocker should be used to treat chronic heart failure? Circulation. 2000 Aug 01; 102(5):484-6.
    View in: PubMed
    Score: 0.144
  26. Bristow MR. Mechanistic and clinical rationales for using beta-blockers in heart failure. J Card Fail. 2000 Jun; 6(2 Suppl 1):8-14.
    View in: PubMed
    Score: 0.142
  27. Lowes BD, Simon MA, Tsvetkova TO, Bristow MR. Inotropes in the beta-blocker era. Clin Cardiol. 2000 Mar; 23(3 Suppl):III11-6.
    View in: PubMed
    Score: 0.139
  28. Bristow MR. beta-adrenergic receptor blockade in chronic heart failure. Circulation. 2000 Feb 08; 101(5):558-69.
    View in: PubMed
    Score: 0.139
  29. Lindenfeld J, Lowes BD, Bristow MR. Hypotension with dobutamine: beta-adrenergic antagonist selectivity at low doses of carvedilol. Ann Pharmacother. 1999 Dec; 33(12):1266-9.
    View in: PubMed
    Score: 0.137
  30. Gwathmey JK, Kim CS, Hajjar RJ, Khan F, DiSalvo TG, Matsumori A, Bristow MR. Cellular and molecular remodeling in a heart failure model treated with the beta-blocker carteolol. Am J Physiol. 1999 05; 276(5):H1678-90.
    View in: PubMed
    Score: 0.132
  31. Piccini JP, Abraham WT, Dufton C, Carroll IA, Healey JS, van Veldhuisen DJ, Sauer WH, Anand IS, White M, Wilton SB, Aleong R, Rienstra M, Krueger SK, Ayala-Paredes F, Khaykin Y, Merkely B, Miloradovic V, Wranicz JK, Ilkhanoff L, Ziegler PD, Davis G, Emery LL, Marshall D, Kao DP, Bristow MR, Connolly SJ. Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial. JACC Heart Fail. 2019 07; 7(7):586-598.
    View in: PubMed
    Score: 0.132
  32. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol. 1998 Dec; 21(12 Suppl 1):I3-13.
    View in: PubMed
    Score: 0.128
  33. Shakar SF, Abraham WT, Gilbert EM, Robertson AD, Lowes BD, Zisman LS, Ferguson DA, Bristow MR. Combined oral positive inotropic and beta-blocker therapy for treatment of refractory class IV heart failure. J Am Coll Cardiol. 1998 May; 31(6):1336-40.
    View in: PubMed
    Score: 0.123
  34. Quaife RA, Christian PE, Gilbert EM, Datz FL, Volkman K, Bristow MR. Effects of carvedilol on right ventricular function in chronic heart failure. Am J Cardiol. 1998 Jan 15; 81(2):247-50.
    View in: PubMed
    Score: 0.120
  35. Bristow M, Port JD. Beta-adrenergic blockade in chronic heart failure. Scand Cardiovasc J Suppl. 1998; 47:45-55.
    View in: PubMed
    Score: 0.120
  36. Bristow MR. Mechanism of action of beta-blocking agents in heart failure. Am J Cardiol. 1997 Dec 04; 80(11A):26L-40L.
    View in: PubMed
    Score: 0.119
  37. Leary PJ, Kronmal RA, Bluemke DA, Buttrick PM, Jones KL, Kao DP, Kawut SM, Krieger EV, Lima JA, Minobe W, Ralph DD, Tedford RJ, Weiss NS, Bristow MR. Histamine H2 Receptor Polymorphisms, Myocardial Transcripts, and Heart Failure (from the Multi-Ethnic Study of Atherosclerosis and Beta-Blocker Effect on Remodeling and Gene Expression Trial). Am J Cardiol. 2018 01 15; 121(2):256-261.
    View in: PubMed
    Score: 0.118
  38. Bristow MR, Abraham WT, Yoshikawa T, White M, Hattler BG, Crisman TS, Lowes BD, Robertson AD, Larrabee P, Gilbert EM. Second- and third-generation beta-blocking drugs in chronic heart failure. Cardiovasc Drugs Ther. 1997 May; 11 Suppl 1:291-6.
    View in: PubMed
    Score: 0.115
  39. Eichhorn EJ, Bristow MR. Practical guidelines for initiation of beta-adrenergic blockade in patients with chronic heart failure. Am J Cardiol. 1997 Mar 15; 79(6):794-8.
    View in: PubMed
    Score: 0.114
  40. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE, Kubo SH, Narahara KA, Ingersoll H, Krueger S, Young S, Shusterman N. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation. 1996 Dec 01; 94(11):2807-16.
    View in: PubMed
    Score: 0.111
  41. Gilbert EM, Abraham WT, Olsen S, Hattler B, White M, Mealy P, Larrabee P, Bristow MR. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation. 1996 Dec 01; 94(11):2817-25.
    View in: PubMed
    Score: 0.111
  42. Quaife RA, Gilbert EM, Christian PE, Datz FL, Mealey PC, Volkman K, Olsen SL, Bristow MR. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy. Am J Cardiol. 1996 Oct 01; 78(7):779-84.
    View in: PubMed
    Score: 0.110
  43. Yoshikawa T, Port JD, Asano K, Chidiak P, Bouvier M, Dutcher D, Roden RL, Minobe W, Tremmel KD, Bristow MR. Cardiac adrenergic receptor effects of carvedilol. Eur Heart J. 1996 Apr; 17 Suppl B:8-16.
    View in: PubMed
    Score: 0.106
  44. Bristow MR, Gilbert EM. Improvement in cardiac myocyte function by biological effects of medical therapy: a new concept in the treatment of heart failure. Eur Heart J. 1995 Jul; 16 Suppl F:20-31.
    View in: PubMed
    Score: 0.101
  45. Olsen SL, Gilbert EM, Renlund DG, Taylor DO, Yanowitz FD, Bristow MR. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study. J Am Coll Cardiol. 1995 May; 25(6):1225-31.
    View in: PubMed
    Score: 0.100
  46. Vehlow C, Kao DP, Bristow MR, Hunter LE, Weiskopf D, Görg C. Visual analysis of biological data-knowledge networks. BMC Bioinformatics. 2015 Apr 29; 16:135.
    View in: PubMed
    Score: 0.100
  47. Taylor MR, Sun AY, Davis G, Fiuzat M, Liggett SB, Bristow MR. Race, common genetic variation, and therapeutic response disparities in heart failure. JACC Heart Fail. 2014 Dec; 2(6):561-72.
    View in: PubMed
    Score: 0.096
  48. Abraham WT, Lowes BD, White M, Ferguson DA, Scheffel CA, Wolfel EE, Lindenfeld J, Bristow MR. Comparative hemodynamic effects of OPC-18790 and dobutamine in patients with advanced heart failure. J Card Fail. 1994 Oct; 1(1):57-62.
    View in: PubMed
    Score: 0.096
  49. Aleong RG, Sauer WH, Davis G, Bristow MR. New-onset atrial fibrillation predicts heart failure progression. Am J Med. 2014 Oct; 127(10):963-71.
    View in: PubMed
    Score: 0.094
  50. Bristow MR, O'Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P, et al. Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Bucindolol Investigators. Circulation. 1994 Apr; 89(4):1632-42.
    View in: PubMed
    Score: 0.093
  51. Bristow MR. Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents. Am J Cardiol. 1993 Mar 25; 71(9):12C-22C.
    View in: PubMed
    Score: 0.086
  52. Gilbert EM, Olsen SL, Renlund DG, Bristow MR. beta-adrenergic receptor regulation and left ventricular function in idiopathic dilated cardiomyopathy. Am J Cardiol. 1993 Mar 25; 71(9):23C-29C.
    View in: PubMed
    Score: 0.086
  53. Kao DP, Wagner BD, Robertson AD, Bristow MR, Lowes BD. A personalized BEST: characterization of latent clinical classes of nonischemic heart failure that predict outcomes and response to bucindolol. PLoS One. 2012; 7(11):e48184.
    View in: PubMed
    Score: 0.084
  54. Bristow MR, Larrabee P, Müller-Beckmann B, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD. Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes. Clin Investig. 1992; 70 Suppl 1:S105-13.
    View in: PubMed
    Score: 0.079
  55. Bristow MR, Larrabee P, Minobe W, Roden R, Skerl L, Klein J, Handwerger D, Port JD, Müller-Beckmann B. Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol. 1992; 19 Suppl 1:S68-80.
    View in: PubMed
    Score: 0.079
  56. Gilbert EM, O'Connell JB, Bristow MR. Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade. Heart Vessels Suppl. 1991; 6:29-39.
    View in: PubMed
    Score: 0.074
  57. Carson P, Fiuzat M, O'Connor C, Anand I, Plehn J, Lindenfeld JA, Silver M, White M, Miller A, Davis G, Robertson AD, Bristow M, Gottlieb S. Determination of hospitalization type by investigator case report form or adjudication committee in a large heart failure clinical trial (ß-Blocker Evaluation of Survival Trial [BEST]). Am Heart J. 2010 Oct; 160(4):649-54.
    View in: PubMed
    Score: 0.073
  58. Hershberger RE, Wynn JR, Sundberg L, Bristow MR. Mechanism of action of bucindolol in human ventricular myocardium. J Cardiovasc Pharmacol. 1990 Jun; 15(6):959-67.
    View in: PubMed
    Score: 0.071
  59. Gilbert EM, Anderson JL, Deitchman D, Yanowitz FG, O'Connell JB, Renlund DG, Bartholomew M, Mealey PC, Larrabee P, Bristow MR. Long-term beta-blocker vasodilator therapy improves cardiac function in idiopathic dilated cardiomyopathy: a double-blind, randomized study of bucindolol versus placebo. Am J Med. 1990 Mar; 88(3):223-9.
    View in: PubMed
    Score: 0.070
  60. Feldman AM, Bristow MR. The beta-adrenergic pathway in the failing human heart: implications for inotropic therapy. Cardiology. 1990; 77 Suppl 1:1-32.
    View in: PubMed
    Score: 0.069
  61. Bristow MR, Port JD, Hershberger RE, Gilbert EM, Feldman AM. The beta-adrenergic receptor-adenylate cyclase complex as a target for therapeutic intervention in heart failure. Eur Heart J. 1989 Jun; 10 Suppl B:45-54.
    View in: PubMed
    Score: 0.066
  62. Taylor MR, Slavov D, Humphrey K, Zhao L, Cockroft J, Zhu X, Lavori P, Bristow MR, Mestroni L, Lazzeroni LC. Pharmacogenetic effect of an endothelin-1 haplotype on response to bucindolol therapy in chronic heart failure. Pharmacogenet Genomics. 2009 Jan; 19(1):35-43.
    View in: PubMed
    Score: 0.064
  63. MacGregor JF, Wachter SB, Munger M, Stoddard G, Bristow MR, Gilbert EM. Carvedilol produces sustained long-term benefits: follow-up at 12 years. Congest Heart Fail. 2009 Jan-Feb; 15(1):5-8.
    View in: PubMed
    Score: 0.064
  64. Tate CW, Robertson AD, Zolty R, Shakar SF, Lindenfeld J, Wolfel EE, Bristow MR, Lowes BD. Quality of life and prognosis in heart failure: results of the Beta-Blocker Evaluation of Survival Trial (BEST). J Card Fail. 2007 Nov; 13(9):732-7.
    View in: PubMed
    Score: 0.059
  65. Lowes BD, Zolty R, Shakar SF, Brieke A, Gray N, Reed M, Calalb M, Minobe W, Lindenfeld J, Wolfel EE, Geraci M, Bristow MR, Cleveland J. Assist devices fail to reverse patterns of fetal gene expression despite beta-blockers. J Heart Lung Transplant. 2007 Nov; 26(11):1170-6.
    View in: PubMed
    Score: 0.059
  66. Bullinga JR, Alharethi R, Schram MS, Bristow MR, Gilbert EM. Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure. J Card Fail. 2005 Dec; 11(9):693-9.
    View in: PubMed
    Score: 0.052
  67. Feldman DS, Carnes CA, Abraham WT, Bristow MR. Mechanisms of disease: beta-adrenergic receptors--alterations in signal transduction and pharmacogenomics in heart failure. Nat Clin Pract Cardiovasc Med. 2005 Sep; 2(9):475-83.
    View in: PubMed
    Score: 0.051
  68. Fowler MB, Bristow MR. Rationale for beta-adrenergic blocking drugs in cardiomyopathy. Am J Cardiol. 1985 Apr 26; 55(10):120D-124D.
    View in: PubMed
    Score: 0.050
  69. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD, Bristow MR, Wolfel EE. Peak oxygen consumption and outcome in heart failure patients chronically treated with beta-blockers. J Card Fail. 2004 Feb; 10(1):15-20.
    View in: PubMed
    Score: 0.046
  70. Domanski M, Krause-Steinrauf H, Deedwania P, Follmann D, Ghali JK, Gilbert E, Haffner S, Katz R, Lindenfeld J, Lowes BD, Martin W, McGrew F, Bristow MR. The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial. J Am Coll Cardiol. 2003 Sep 03; 42(5):914-22.
    View in: PubMed
    Score: 0.044
  71. Linseman JV, Bristow MR. Drug therapy and heart failure prevention. Circulation. 2003 Mar 11; 107(9):1234-6.
    View in: PubMed
    Score: 0.043
  72. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L. Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J Am Coll Cardiol. 2002 Oct 02; 40(7):1248-58.
    View in: PubMed
    Score: 0.042
  73. Cleland JGF, Bristow MR, Freemantle N, Olshansky B, Gras D, Saxon L, Tavazzi L, Boehmer J, Ghio S, Feldman AM, Daubert JC, de Mets D. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual patient data meta-analysis of COMPANION and CARE-HF. Eur J Heart Fail. 2022 06; 24(6):1080-1090.
    View in: PubMed
    Score: 0.041
  74. Lindenfeld J, Robertson AD, Lowes BD, Bristow MR. Aspirin impairs reverse myocardial remodeling in patients with heart failure treated with beta-blockers. J Am Coll Cardiol. 2001 Dec; 38(7):1950-6.
    View in: PubMed
    Score: 0.039
  75. Port JD, Bristow MR. beta-Adrenergic receptors, transgenic mice, and pharmacological model systems. Mol Pharmacol. 2001 Oct; 60(4):629-31.
    View in: PubMed
    Score: 0.039
  76. Piccini JP, Dufton C, Carroll IA, Healey JS, Abraham WT, Khaykin Y, Aleong R, Krueger SK, Sauer WH, Wilton SB, Rienstra M, van Veldhuisen DJ, Anand IS, White M, Camm AJ, Ziegler PD, Marshall D, Bristow MR, Connolly SJ. Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the ADRB1 Arg389Arg Genotype. Circ Arrhythm Electrophysiol. 2021 08; 14(8):e009591.
    View in: PubMed
    Score: 0.038
  77. Asano K, Zisman LS, Yoshikawa T, Headley V, Bristow MR, Port JD. Bucindolol, a nonselective beta 1- and beta 2-adrenergic receptor antagonist, decreases beta-adrenergic receptor density in cultured embryonic chick cardiac myocyte membranes. J Cardiovasc Pharmacol. 2001 Jun; 37(6):678-91.
    View in: PubMed
    Score: 0.038
  78. Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med. 2001 05 31; 344(22):1659-67.
    View in: PubMed
    Score: 0.038
  79. Fowler MB, Vera-Llonch M, Oster G, Bristow MR, Cohn JN, Colucci WS, Gilbert EM, Lukas MA, Lacey MJ, Richner R, Young ST, Packer M. Influence of carvedilol on hospitalizations in heart failure: incidence, resource utilization and costs. U.S. Carvedilol Heart Failure Study Group. J Am Coll Cardiol. 2001 May; 37(6):1692-9.
    View in: PubMed
    Score: 0.038
  80. Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000 Jun; 6(2):115-9.
    View in: PubMed
    Score: 0.035
  81. Lowes BD, Gill EA, Abraham WT, Larrain JR, Robertson AD, Bristow MR, Gilbert EM. Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol. 1999 Apr 15; 83(8):1201-5.
    View in: PubMed
    Score: 0.033
  82. Bristow MR. Mechanisms of development of heart failure in the hypertensive patient. Cardiology. 1999; 92 Suppl 1:3-6; discussion 7-9, 20-1.
    View in: PubMed
    Score: 0.032
  83. Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA. Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group. J Card Fail. 1997 Sep; 3(3):173-9.
    View in: PubMed
    Score: 0.029
  84. Colucci WS, Packer M, Bristow MR, Gilbert EM, Cohn JN, Fowler MB, Krueger SK, Hershberger R, Uretsky BF, Bowers JA, Sackner-Bernstein JD, Young ST, Holcslaw TL, Lukas MA. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996 Dec 01; 94(11):2800-6.
    View in: PubMed
    Score: 0.028
  85. Cleland JG, Bristow MR, Erdmann E, Remme WJ, Swedberg K, Waagstein F. Beta-blocking agents in heart failure. Should they be used and how? Eur Heart J. 1996 Nov; 17(11):1629-39.
    View in: PubMed
    Score: 0.028
  86. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23; 334(21):1349-55.
    View in: PubMed
    Score: 0.027
  87. Hinterberg MA, Kao DP, Bristow MR, Hunter LE, Port JD, Görg C. Peax: interactive visual analysis and exploration of complex clinical phenotype and gene expression association. Pac Symp Biocomput. 2015; 419-30.
    View in: PubMed
    Score: 0.024
  88. Port JD, Debellis CC, Klein J, Peeters GA, Barry WH, Bristow MR. Pharmacological characterization of chick and frog beta adrenergic receptors in primary cultures of myocardial cells. J Pharmacol Exp Ther. 1992 Jul; 262(1):217-24.
    View in: PubMed
    Score: 0.020
  89. Bristow MR. The beta-adrenergic receptor. Configuration, regulation, mechanism of action. Postgrad Med. 1988 Feb 29; Spec No:19-26.
    View in: PubMed
    Score: 0.015
  90. Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S, et al. Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res. 1986 Sep; 59(3):297-309.
    View in: PubMed
    Score: 0.014
  91. Bristow MR, Kantrowitz NE, Ginsburg R, Fowler MB. Beta-adrenergic function in heart muscle disease and heart failure. J Mol Cell Cardiol. 1985 Jul; 17 Suppl 2:41-52.
    View in: PubMed
    Score: 0.013
  92. Bristow MR, Green RD. Effect of diazoxide, verapamil and compound D600 on isoproterenol and calcium-mediated dose-response relationships in isolated rabbit atrium. Eur J Pharmacol. 1977 Oct 01; 45(3):267-79.
    View in: PubMed
    Score: 0.007
  93. Bristow M, Green RD. A quantitative study of beta-adrenergic receptors in rabbit atria. Eur J Pharmacol. 1970 Sep 01; 12(1):120-3.
    View in: PubMed
    Score: 0.005
  94. Bristow M. Vasodilation in treatment of hypertension. N Engl J Med. 1970 May 07; 282(19):1102.
    View in: PubMed
    Score: 0.004
  95. Bristow M, Sherrod TR, Green RD. Analysis of beta receptor drug interactions in isolated rabbit atrium, aorta, stomach and trachea. J Pharmacol Exp Ther. 1970 Jan; 171(1):52-61.
    View in: PubMed
    Score: 0.004
  96. Schroeder JS, Beier-Scott L, Ginsburg R, Bristow MR, McAuley BJ. Efficacy of diltiazem for medically refractory stable angina: long-term follow-up. Clin Cardiol. 1985 Sep; 8(9):480-5.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)